XBiotech (XBIT) Total Non-Current Liabilities (2014 - 2026)

XBiotech has reported Total Non-Current Liabilities for 13 years, with the latest figure at $3.4 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 12.94% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was $3.4 million, a 12.94% decrease from a year earlier, with the FY2025 full-year figure at $7.9 million, down 47.47% from the prior year.
• Total Non-Current Liabilities was $3.4 million for Q2 2026 at XBiotech, down from $7.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $17.1 million in Q2 2024, with the low at $3.4 million in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $7.7 million, with a median of $5.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities surged 366.67% in 2024, then sank 77.71% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $4.1 million in 2022, then soared by 47.88% to $6.1 million in 2023, then jumped by 147.62% to $15.1 million in 2024, then slumped by 47.47% to $7.9 million in 2025, then sank by 57.68% to $3.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $3.4 million (Q2 2026), $7.9 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.